Trial Profile
A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 22 Sep 2015 New trial record
- 14 Sep 2015 Results published in the Bone Marrow Transplantation.